UMC Raises 2026 Capital Expenditure to $2 Billion for Wafer Fab Expansion
0xBroomberg
UMC's board approved a phased capacity expansion, raising 2026 capex to $2 billion to enlarge its Singapore cleanroom and build a new fab shell in Tainan. This means → AI-driven demand for mature-node chips is now large enough to unlock fresh foundry spending.
What is UMC building, and where?
Two tracks running in parallel: expanding cleanroom capacity in Singapore and constructing a new fab shell at the flagship Tainan campus in Taiwan.
CEO Jason Wang stressed "phased execution" — build the shell first, install equipment as orders firm up, no lump-sum spend.
This means → UMC wants flexibility over speed, keeping capital discipline while staying ready to ramp when customers commit.
Why mature nodes, not leading edge?
UMC plays a completely different game from TSMC: TSMC races toward 2 nm and 1 nm; UMC focuses on mature process nodes — chip manufacturing at larger geometries with well-proven technology.
The expansion is driven by AI applications pulling demand for mature chips — AI systems need not only cutting-edge processors but also high volumes of power-management ICs, sensors, and driver chips made on older processes.
In plain terms = the AI boom is not just about building the most advanced chips; orders for the "ordinary chips" that support AI systems are surging too.
How does UMC's financial picture look right now?
Q2 revenue reached NT$68.73 billion (roughly $2.12 billion), up 17% year-on-year.
Net profit hit NT$42.26 billion, soaring 374.7% year-on-year — profit growth far outpaced revenue growth.
This reflects improving utilization rates and pricing power at mature nodes: not just more volume, but better pricing too.
The stock has already doubled — where is the risk?
UMC shares have risen 120% year-to-date, well ahead of the Taiwan Weighted Index's 38.24% gain over the same period.
Yet on Wednesday — the day before earnings — the stock fell 9.69% in a single session as the market took profits at elevated levels.
This means → the key question is no longer "can UMC win orders?" but "can the new capacity actually be filled?" — utilization rate is the metric that will validate or break this expansion thesis.
Content is for reference only, not financial advice.